In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targeted Molecular Diagnostics LLC

Division of IQVIA
www.tmdlab.com

Latest From Targeted Molecular Diagnostics LLC

What New Her2 Tests Say about Personalized Medicine

Traditional diagnostic tests for Her2 (the target of the drug Herceptin) have well-documented failings. In July, Monogram Biosciences launched a new Her2 test, and two months later, Genomic Health added Her2 status information to its breast cancer test. They believe that more comprehensive, multianalyte tests may better guide therapy and yield a pharmacoeconomic benefit, even at eight to 10 times the cost. These developments point to the need for a more nuanced approach to the management of cancer as a chronic disease and a more nuanced view of personalized medicine.
Medical Device Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • IQVIA
  • Senior Management
  • Sarah Bacus, PhD, Pres., CEO & CSO
    Christopher Ung, VP, Bus. Dev. & Mktg.
  • Contact Info
  • Targeted Molecular Diagnostics LLC
    Phone: (630) 789-1233
    610 Oakmont Ln.
    Westmont, IL 60559
    USA
UsernamePublicRestriction

Register